TY - JOUR
T1 - Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease
AU - Subramaniyam, Veerappan
AU - Waller, Edmund K.
AU - Murrow, Jonathan R.
AU - Manatunga, Amita
AU - Lonial, Sagar
AU - Kasirajan, Karthikeswar
AU - Sutcliffe, Diane
AU - Harris, Wayne
AU - Taylor, W. Robert
AU - Alexander, R. Wayne
AU - Quyyumi, Arshed A.
N1 - Funding Information:
This study was supported by grants from Berlex Oncology, the Emory General Clinical Research Center grant MO1-RR00039, and a grant from the Vascular Biology Working Group. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the article, and its final content.
PY - 2009/7
Y1 - 2009/7
N2 - Background: We hypothesized that granulocyte macrophage colony-stimulating factor (GM-CSF) administration will be safe and will improve endothelial dysfunction and exercise capacity by mobilizing progenitor cells in patients with peripheral arterial disease (PAD). Methods: Forty-five patients with PAD received thrice-weekly injections for 2 weeks of 3, 6, or 10 μg/kg per day of GM-CSF or placebo in successive cohorts of 15 subjects randomized 2:1 to drug or placebo. CD34+ mononuclear cell subsets and colony formation assay, endothelial function, ankle-brachial index, and walking capacity were measured. Results: Granulocyte macrophage colony-stimulating factor administration was safe. After pooling data from GM-CSF cohorts, at 2 weeks, there was a significant increase in total leukocytes (43%, P < .0001), CD34+ cells (46%, P = .035), and colony-forming units (31%, P = .026, week 1). At 12 weeks, endothelial function improved with GM-CSF (flow-mediated vasodilation increased by 59%, P < .01) as did pain-free treadmill walking time (38 seconds, P = .008) and total treadmill walking time (55 seconds, P = .016). Corresponding changes were not observed in the placebo group. Conclusions: Granulocyte macrophage colony-stimulating factor therapy in patients with PAD was associated with mobilization of progenitor cells, improvement of endothelial dysfunction, and exercise capacity. The efficacy of strategies designed to mobilize bone marrow progenitors warrants further study in patients with PAD.
AB - Background: We hypothesized that granulocyte macrophage colony-stimulating factor (GM-CSF) administration will be safe and will improve endothelial dysfunction and exercise capacity by mobilizing progenitor cells in patients with peripheral arterial disease (PAD). Methods: Forty-five patients with PAD received thrice-weekly injections for 2 weeks of 3, 6, or 10 μg/kg per day of GM-CSF or placebo in successive cohorts of 15 subjects randomized 2:1 to drug or placebo. CD34+ mononuclear cell subsets and colony formation assay, endothelial function, ankle-brachial index, and walking capacity were measured. Results: Granulocyte macrophage colony-stimulating factor administration was safe. After pooling data from GM-CSF cohorts, at 2 weeks, there was a significant increase in total leukocytes (43%, P < .0001), CD34+ cells (46%, P = .035), and colony-forming units (31%, P = .026, week 1). At 12 weeks, endothelial function improved with GM-CSF (flow-mediated vasodilation increased by 59%, P < .01) as did pain-free treadmill walking time (38 seconds, P = .008) and total treadmill walking time (55 seconds, P = .016). Corresponding changes were not observed in the placebo group. Conclusions: Granulocyte macrophage colony-stimulating factor therapy in patients with PAD was associated with mobilization of progenitor cells, improvement of endothelial dysfunction, and exercise capacity. The efficacy of strategies designed to mobilize bone marrow progenitors warrants further study in patients with PAD.
UR - http://www.scopus.com/inward/record.url?scp=67049171095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67049171095&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2009.04.014
DO - 10.1016/j.ahj.2009.04.014
M3 - Article
C2 - 19540392
AN - SCOPUS:67049171095
SN - 0002-8703
VL - 158
SP - 53-60.e1
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -